A Review of the Research on DNA Methylation Mediated Epigenetic Remodeling of HRD and Immune Microenvironment in Acquired Resistance to PARP Inhibitors in Ovarian Cancer

Pengxue Zhang

doi:10.62051/ijphmr.v6n3.05

Authors

Pengxue Zhang

DOI:

https://doi.org/10.62051/ijphmr.v6n3.05

Keywords:

Ovarian cancer, PARP inhibitors, Acquired resistance, DNA methylation

Abstract

Adenosine diphosphate ribose polymerase (PARP) inhibitors have become an important targeted therapy for ovarian cancer patients carrying homologous recombination repair defects (HRD), but acquired resistance severely limits the long-term benefits of PARP inhibitors. Recent studies have shown that epigenetic remodeling mediated by DNA methylation plays an important role in the resistance process of PARP inhibitors. Therefore, in addition to inducing HRD phenotype reversal by silencing homologous recombination repair related genes, it can also synergistically mediate drug resistance by regulating the tumor immune microenvironment. This article reviews the epigenetic reversal of HRD and its impact on the immune microenvironment in ovarian cancer PARPi acquired resistance through DNA methylation. This article further introduces the application prospects, existing problems, and future prospects of demethylation drugs combined with PARP inhibitors or immunotherapy for DNA methylation, providing a new theoretical basis and possible approaches for solving clinical drug resistance.

References

[1] Queenie Chen, Jigme P Dorji, Sandali G Perera, Petvy Li, Fizza Aijaz, Linda C Ihuoma, Hiroshi Matsui, Chidiebere U Awah. In vivo inhibition of c-MYC in the metastatic drug-resistant ovarian cancer cells down regulates the c-MYC-PD-L1-PAX8-p21 to achieve therapeutic efficacy [J]. BMC cancer, 2025, 26 (1): 68-68.

[2] Hiroyuki Yoshida, Jiarui Li, Hiroaki Inui, Kyuji Rokugawa, Keiichi Fujiwara. RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer [J]. Scientific Reports, 2025, 15 (1): 38089-38089.

[3] Liu Chaohua, Li Jiana, Xu Fei, Chen Lihua, Ni Mengdong, Wu Jiangchun, Zhao Haiyun, Wu Yangjun, Li Jiajia, Wu Xiaohua, Chen Xiaojun. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer [J]. Molecular Cancer, 2024, 23 (1): 111-111.

[4] Wethington Stephanie L, Shah Payal D, Martin Lainie, Tanyi Janos L, Latif Nawar, Morgan Mark, Torigian Drew A, Rodriguez Diego, Smith Simon A, Dean Emma, Domchek Susan M, Drapkin Ronny, Shih IeMing, Brown Eric J, Hwang WeiTing, Armstrong Deborah K, Gaillard Stephanie, Giuntoli Robert, Simpkins Fiona. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer [J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2023, 29 (15):

[5] Sauriol Alexandre, Carmona Euridice, Udaskin Molly L, Radulovich Nikolina, LeclercDesaulniers Kim, Rottapel Robert, Oza Amit M, Lheureux Stephanie, Provencher Diane M, MesMasson AnneMarie. Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly (ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer [J]. Scientific reports, 2023, 13 (1): 3334-3334.

[6] Perez Fidalgo J.A., Sanchez-Serrano P., Heredia V., Martinez Pretel J.J., Hochstadt J., Mendiola M., Redondo Sanchez A., Burgués O., Pineda Merlo B. 585P Trabectedin induces apoptosis regardless of acquired resistance to PARP inhibitors in BRCA2 mutant high grade ovarian cancer cell lines [J]. Annals of Oncology, 2022, 33 (S7): S814-S814.

[7] Nesic Ksenija, Kondrashova Olga, Hurley Rachel M, McGehee Cordelia D, Vandenberg Cassandra J, Ho GwoYaw, Lieschke Elizabeth, Dall Genevieve, Bound Nirashaa, ShieldArtin Kristy, Radke Marc, Musafer Ashan, Chai Zi Qing, Eftekhariyan Ghamsari Mohammad Reza, Harrell Maria I, Kee Damien, Olesen Inger, McNally Orla, Traficante Nadia, Cancer Study Australian Ovarian, DeFazio Anna, Bowtell David D L, Swisher Elizabeth M, Weroha S John, Nones Katia, Waddell Nicola, Kaufmann Scott H, Dobrovic Alexander, Wakefield Matthew J, Scott Clare L. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma [J]. Cancer research, 2021, 81 (18): 4709-4722.

[8] Wethington Stephanie L., Shah Payal D, Martin Lainie P., Tanyi Janos Laszlo, Latif Nawar A., Morgan Mark Aloysuis, Torigian Drew A., Pagan Cheyenne, Rodriguez Diego, Domchek Susan M., Drapkin Ronny, Shih Ie Ming, Smith Simon, Dean Emma, Armstrong Deborah Kay, Gaillard Stephanie, Simpkins Fiona. Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer [J]. Journal of Clinical Oncology, 2021, 39 (15S): 5516-5516.

[9] Kondrashova Olga, Nguyen Minh, Shield-Artin Kristy, Tinker Anna V, Teng Nelson N H, Harrell Maria I, Kuiper Michael J, Ho Gwo-Yaw, Barker Holly, Jasin Maria, Prakash Rohit, Kass Elizabeth M, Sullivan Meghan R, Brunette Gregory J, Bernstein Kara A, Coleman Robert L, Floquet Anne, Friedlander Michael, Kichenadasse Ganessan, O'Malley David M, Oza Amit, Sun James, Robillard Liliane, Maloney Lara, Bowtell David, Giordano Heidi, Wakefield Matthew J, Kaufmann Scott H, Simmons Andrew D, Harding Thomas C, Raponi Mit. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma [J]. Cancer discovery, 2017, 7 (9): 984-998.

[10] K. Lin, A.V. Tinker, O. Kondrashova, G. Ho, M. Wakefield, R.L. Coleman, D.M. O'Malley, A. Floquet, J. Sun, L. Maloney, H. Giordano, T. Harding, M. Raponi, I.A. McNeish, E. Swisher, C.L. Scott. Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer [J]. European Journal of Cancer, 2016, 69 (S1): S13-S13.